Evidence map›Paper›PMID 40585875›Full record

ArticleTherapeutic advances in medical oncology2025

Frequency of driver oncogenic alterations in NSCLC and estimated indoor radon exposure in Europe (RADON EUROPE study).

Miguel García-Pardo, Marta García de Herreros, Edouard Auclin, Miquel Ferriol-Galmes, Juan Carlos Laguna, Teresa Gorría, Gerard Caravaca, Joan Sart, Víctor Albarrán-Artahona, Rafael López-Castro and 16 more

Abstract read
In one paragraph

Article in Therapeutic advances in medical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Miguel García-PardoMedical Oncology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain.ORCID https://orcid.org/0000-0001-6339-8501
Marta García de HerrerosMedical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Edouard AuclinHôpital Européen Georges Pompidou, APHP, Paris, France.
Miquel Ferriol-GalmesTranslational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.
Juan Carlos LagunaMedical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Teresa GorríaDepartment of Medicine, University of Barcelona, Barcelona, Spain.
Gerard CaravacaMedical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Joan SartMedical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Víctor Albarrán-ArtahonaInstitut Gustave Roussy, Villejuif, France.
Rafael López-CastroHospital Clínico Universitario de Valladolid, Valladolid, Spain.
Cristina TeixidóDepartment of Medicine, University of Barcelona, Barcelona, Spain.ORCID https://orcid.org/0000-0002-7226-6567
Giancarlo CastellanoMedical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Alex Martínez BedmarBioinformatics Area, School of International Studies, ESCI-UPF, Barcelona, Spain.
Ainara ArcochaMedical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Laura AlcoleaTranslational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.
Manuel JiménezTranslational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.
Mario BernabeuTranslational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.ORCID https://orcid.org/0009-0001-1193-3389
David Delgado-CanoTranslational Genomics and Targeted Therapies in Solid Tumors, IDIBAPS, Barcelona, Spain.
Alejandro NavarroMedical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.
Aleix PratDepartment of Medicine, University of Barcelona, Barcelona, Spain.
Noemí ReguartMedical Oncology Department, Hospital Clinic of Barcelona, Barcelona, Spain.ORCID https://orcid.org/0000-0001-8190-499X
Javier ElioDepartment of Mechanical and Marine Engineering, Western Norway University of Applied Sciences, Haugesund, Norway.
Pilar GarridoMedical Oncology Department, Hospital Universitario Ramon y Cajal, Madrid, Spain.ORCID https://orcid.org/0000-0002-5899-6125
Natasha B LeighlPrincess Margaret Cancer Centre, Toronto, Canada.
Benjamin BesseInstitut Gustave Roussy, Villejuif, France.
Laura MezquitaMedical Oncology Department, Hospital Clinic of Barcelona, Carrer de Villarroel, 170, L'Eixample, Barcelona 08036, Spain.ORCID https://orcid.org/0000-0003-0936-7338

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Geographical variations in the frequency of oncogenic driver alterations in non-small cell lung cancer (NSCLC) are observed worldwide, likely influenced by genetic and environmental factors. Radon, a leading cause of lung cancer in nonsmokers, may influence NSCLC's molecular profile. Objectives: This study aims to explore the potential correlation between estimated indoor radon concentrations and the frequency of driver alterations in NSCLC across Europe. Design: Ecological study of European countries with available data on indoor radon exposure (estimated mean levels and the proportion (%) of dwellings with concentrations >200 and >400 Bq/m Methods: We retrospectively analyzed NSCLC molecular data and radon exposure levels from European countries. Radon data, including the mean and proportion (%) of dwellings with concentrations >200 and >400 Bq/m Results: Data on radon exposure and Conclusion: We found a positive correlation between estimated

Indexed as

ALKEGFRepidemiologygenomic testingnon-small cell lung cancer (NSCLC)radon

Identifiers

PMID40585875
PMCPMC12202949

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.